Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

Cougar Goes Public Through Reverse Merger, Raises $47M

April 10, 2006

By Jennifer Boggs

Aastrom Raising $25M For Adult Stem Cell Technology

April 7, 2006

By Jennifer Boggs

Aastrom Raising $25M For Adult Stem Cell Technology

April 7, 2006

By Jennifer Boggs

QLT, Retinagenix To Collaborate On Synthetic Retinoid Program

April 6, 2006

By Jennifer Boggs

QLT, Retinagenix To Collaborate On Synthetic Retinoid Program

April 6, 2006

By Jennifer Boggs

Biogen Selling Amevive Rights To Astellas For $60M, Royalties

April 5, 2006

By Jennifer Boggs

Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today)

Biogen Selling Amevive Rights To Astellas For $60M, Royalties

April 5, 2006

By Jennifer Boggs

Biogen Idec Inc. agreed to sell worldwide rights of its commercially disappointing psoriasis biologic, Amevive, to Astellas Pharma US Inc. in exchange for $60 million plus royalties. (BioWorld Today)

Merrimack's Series E: $65M For Autoimmune, Oncology

April 4, 2006

By Jennifer Boggs

Merrimack's Series E: $65M For Autoimmune, Oncology

April 4, 2006

By Jennifer Boggs

Medarex Begins Second Pivotal Study Of MDX-010 In Melanoma

April 3, 2006

By Jennifer Boggs

View All Articles by Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...